Argenx Enters Japan With Smooth Approval – How Was It Possible?
Strategy Behind Unusual Move
Executive Summary
Belgian bioventure Argenx has made an unusually smooth commercial entry to Japan with Vyvgart almost as fast as the launch of the myasthenia gravis drug in the US. Its founder admits it was a “bold move” for a European pharma company and revealed how the unexpected entrance was made possible.
You may also be interested in...
Argenx CEO Shares Secrets Of Vyvgart’s Stellar Success
Leaving commercial hires to just a few months before drug approval is a mistake, Argenx CEO Tim Van Hauwermeiren told In Vivo sister publication Scrip, noting that the impressive launch achieved for Vyvgart for generalized myasthenia gravis in the US and Japan will be a steadier affair in Europe.
Argenx CEO Shares Secrets Of Vyvgart’s Stellar Success
Leaving commercial hires to just a few months before drug approval is a mistake, Argenx CEO Tim Van Hauwermeiren tells Scrip, noting that the impressive launch achieved for Vyvgart for generalized myasthenia gravis in the US and Japan will be a steadier affair in Europe.
BioMarin’s Roctavian & Argenx’s Efgartigimod Among Eight Hopefuls Awaiting EU Verdict
Will BioMarin be second time lucky with its hemophilia gene therapy Roctavian in the EU? The European Medicines Agency could soon decide whether the product should be approved.